Table 1.
Staining index for 12 PcG proteins in four groups of ovarian tumor tissues
| PcG proteins (n=12) | Primary ovarian tumor tissues at resentation (n=100×2) |
Abdominal disseminated lesions at presentation (n=100×2) |
Lymph node metastatic lesions at presentation (n=50×2) |
Recurrent tumor tissues at relapse (n=50×2) |
Primary tumors tissues vs lymph node metastatic lesions P-value* |
Primary tumor tissues vs recurrent tumor tissues P-value* |
|---|---|---|---|---|---|---|
| BMI1 | 7.68±3.48 | 7.92±3.33 | 8.07±3.10 | 9.96±3.33 | 0.03 | <0.001 |
| MEL18 | 7.50±2.53 | 7.16±2.50 | 7.05±2.14 | 7.95±2.76 | \ | \ |
| RING1 | 5.07±1.83 | 5.33±2.47 | 5.38±1.58 | 6.98±3.31 | \ | <0.001 |
| RING2 | 5.64±1.50 | 5.66±1.26 | 5.97±0.99 | 6.44±1.84 | 0.041 | <0.001 |
| CBX2 | 5.29±1.07 | 5.37±1.15 | 5.35±0.78 | 5.49±1.28 | \ | <0.001 |
| CBX4 | 7.01±2.77 | 6.99±2.98 | 6.93±1.81 | 8.36±3.31 | \ | 0.034 |
| PHC1 | 6.70±3.09 | 6.44±3.27 | 6.57±1.87 | 6.72±2.90 | \ | \ |
| PHF1 | 7.20±3.16 | 7.35±3.18 | 7.24±2.06 | 8.12±3.16 | \ | 0.017 |
| RYBP | 6.22±2.48 | 6.10±2.75 | 6.29±2.36 | 6.43±2.40 | \ | \ |
| EZH2 | 7.35±3.17 | 8.01±3.34 | 9.08±3.79 | 9.82±3.87 | 0.028 | <0.001 |
| EED | 6.10±2.50 | 5.88±2.16 | 6.03±2.05 | 5.94±2.33 | \ | \ |
| SUZ12 | 6.43±2.16 | 6.36±2.39 | 6.33±1.14 | 6.69±2.48 | \ | \ |
Notes:
*
Wilcoxon signed rank test. A semi-quantitative scoring criterion is used, and a staining index (values 1 to 16), obtained as the intensity of positive staining (negative =1, weak =2, moderate =3, or strong =4 scores) and the proportion of immunopositive cells of interest (≦10% =1, >10% to ≦50% =2, >50% to ≦70% =3, >75% =4 scores), is calculated. Proteins that show significant expression differences between primary and recurrent tumor tissues are shown in bold.
Abbreviation: PcG, polycomb group.